Neoadjuvant Transcatheter Arterial Chemoembolization and Systemic Chemotherapy for the Treatment of Wilms Tumor

Wilms Tumor ◽  
2016 ◽  
pp. 95-112 ◽  
Author(s):  
Min-Ju Li ◽  
◽  
Da-Xing Tang ◽  
Shan Xu ◽  
Yong Huang ◽  
...  
Keyword(s):  
Systemic Chemotherapy ◽  
Transcatheter Arterial Chemoembolization ◽  
Wilms Tumor ◽  
Arterial Chemoembolization

Gemcitabine-based transcatheter arterial chemoembolization for unresectable cholangiocarcinoma in thirty-eight patients: Single institutional experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14152-14152
Author(s):  
T. C. Gamblin ◽  
D. A. Geller ◽  
J. W. Marsh ◽  
B. Carr
Keyword(s):  
Systemic Chemotherapy ◽  
Transcatheter Arterial Chemoembolization ◽  
Single Agent ◽  
Institutional Experience ◽  
Grade 3 ◽  
Age Range ◽  
Actual Survival ◽  
Gemcitabine And Cisplatin ◽  
Arterial Chemoembolization

14152 Background: Survival for patients with unresectable cholangiocarcinoma is reported to be 5–8 months. Systemic chemotherapy has been disappointing and not shown to significantly improve survival. Transcatheter arterial chemoembolization (TACE) has been shown to prolong survival in hepatocellular carcinoma patients but experience with cholangiocarcinoma is limited. We report our experience with the well-tolerated drug gemcitabine. Methods: Thirty-eight patients with unresectable cholangiocarcinoma were treated with one or more cycles of gemcitabine-based TACE between 2001 and 2005 at our institution. Follow-up imaging was performed on all patients after each TACE procedure. Regimens of TACE included: gemcitabine only (16), gemcitabine followed by cisplatin (2), gemcitabine followed by oxaliplatin (5), gemcitabine and cisplatin (12), and gemcitabine and cisplatin followed by oxaliplatin (3). Actual survival is reported, as 35 of 38 have died from disease (92%). Results: Patients were 57.5 years of age (range 36–87) and a median of 3 treatments (range 1–10) were administered. Median survival from time of first treatment was 10.3 months. Patients receiving gemcitabine followed by cisplatin or oxaliplatin had improved survival (mean 16.5 and 10.5 months respectively) when compared to gemcitabine alone (mean 6 months). Patients receiving gemcitabine and cisplatin as a combination had improved survival (mean 13.4 months) compared to single agent gemcitabine. Patients who progressed on gemcitabine and cisplatin and then received oxaliplatin also showed improved survival (mean 14.3 months) compared to gemcitabine only. Neutropenia, thrombocytopenia and hyperbilirubinemia were the most common toxicities observed. Three patients in the entire series exhibited grade 3 thrombocytopenia while seven patients had grade 3 and one had grade 4 bilirubin levels. Conclusions: This series provides evidence in favor of TACE rather than historically reported alternatives such as systemic chemotherapy or chemotherapy/RT. Our results suggest that gemcitabine based TACE is well tolerated and perhaps best delivered as a combination therapy for patients with unresectable cholangiocarcinoma. No significant financial relationships to disclose.

Radial Artery Approach for Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma

2002 ◽  
Vol 46 (3) ◽  
pp. 229
Author(s):  
Seung Hun Ryu ◽  
Hyung Jin Shim ◽  
Byung Kook Kwak ◽  
Gi Hyun Kim ◽  
Hwa Yeon Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radial Artery ◽  
Transcatheter Arterial Chemoembolization ◽  
Arterial Chemoembolization
Sign in / Sign up

Export Citation Format

Share Document